News
IPO launch on Euronext Paris
AFFLUENT MEDICAL launches its IPO on the regulated Euronext Paris market • Capital increase of approximately €33.0 million, which may be increased to approximately €43.6 million in the event of the full exercise of the extension and over-allotment...
Epygon publication
Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency. • Preclinical in vivo results published...
Approval of the Registration Document
AFFLUENT MEDICAL announces the approval of its Registration Document by the French Financial Markets Authority (Autorité des marchés financiers – AMF) as part of its proposed IPO on the Euronext Paris regulated market Affluent Medical, a French...
Affluent Medical announces 15.8m€ in new financing and strengthening of its board of Directors
The Private Placement Financing was taken out for gross proceeds of €10.3 million, €8 million via convertible bonds (of which €4 million were received in December 2019). Affluent Medical has been granted two “PGE” (government-backed) loans for a...
Affluent Medical announces the launch of MINERVA First-In-Human clinical study for EPYGON
Epygon is the first transcatheter mitral valve designed to restore the physiological blood flow vortex and treat left ventricle disease, in particular in so-called “functional” patients. No mitral valve prosthesis currently on the market or in...
Affluent Medical announces first patient implanted in OPTIMISE II pivotal clinical study for KALIOS, the minimally invasive mitral valve repair ring
KALIOS is the first fully adjustable mitral valve repair ring, designated for the percutaneous treatment of both residual and recurrent Mitral Regurgitation (MR). First patient implanted in Vienna General Hospital (AKH) Obtention of regulatory...
